Product Description
| Download Documents | |
| SDS | USER MANUAL will be supplied to customer |
AqT® Biotin ADC Labeling kit is a proprietary biotinylation kit developed at CellMosaic® for obtaining biotin labeled ADC.
AqT® Biotin ADC Labeling Kit (Surface Amines) enables biotinylation of antibody–drug conjugates (ADCs) for detection, which can be challenging with conventional linker chemistries due to aggregation. The kit is designed for dual labeling, producing ADCs with an average of 3-5 drugs and 2–4 biotins per antibody. It uses CellMosaic’s super-hydrophilic, water-soluble, charge-neutral AqT® linker to minimize additional aggregation during biotinylation and generates stable dual labeled conjugates while helping preserve ADC function.
For a detailed description of the AqT® technologies, please see our technology section.
This kit is not a standalone kit and must be used with CellMosaic ADC kit workflows; it is intended for use directly with ADC intermediates generated in those workflows (see Table 1 for compatible kits).
The CM86145 kit is designed to label selected IgG ADCs prepared using CellMosaic's ADC kits with AqT® bitcoin via surface amines on the antibody. The kit includes AqT® biotin acid, which is activated within 15 minutes and then coupled directly to the ADC in one step within 1 hour. The labeled product is subsequently purified to remove any unreacted AqT® biotin acid
|
Catalog Number |
Number of Reactions in Kit |
Antibody Amount per Reaction |
|
CM86145.01x1 |
1 |
100 μg (0.667 nmol for IgG) |
|
CM86145.01x3 |
3 |
|
|
CM86145x1 |
1 |
1-3 mg (6.67-20 nmol for IgG) |
|
CM86145x3 |
3 |
If you have any other customization needs, please provide the details above.
Compatible CellMosaic ADC Kits for use with CM86264
| Part # (Number of Reactions) | ADC Kit Name (Scale of the Reaction) |
| CM11409 (x1, x3) | Antibody MMAE Conjugation Kit (With VC-PAB Linker) (1-3 mg) |
| CM11416 (x1, x3) | F(ab’)2 MMAE Conjugation Kit (with VC-PAB Linker) (1-3 mg) |
| CM11422 (x1, x3) | Antibody Mc-MMAF Conjugation Kit (1-3 mg) |
| CM11425 (x1, x3) | Antibody MMAF Conjugation Kit (with VC-PAB Linker) (1-3 mg) |
| CM11429 (x1, x3) | ADC Control Kit with VC-PAB Linker (1-3 mg) |
| CM11431 (x1, x3) | Antibody Deruxtecan Conjugation Kit (1-3 mg) |
Key Features
- Advanced AqT® linker technology: Utilizes CellMosaic’s proprietary, super-hydrophilic, water-soluble, charge-neutral AqT® linker to minimize fluorophore stacking and ADC aggregation.
- High biotin loading with preserved ADC properties: Typical degree of labeling (DOL) of 2–4 dyes per ADC while maintaining ADC activity, with minimum aggregation.
- All-inclusive kit with validated analytical method: Provides sterilized buffers and tubes, columns, and filters for biotinylation. Also includes all buffers and methods needed for concentration measurement and loading determination.
- Fast, user-friendly workflow plus optional support: One-step labeling and purification in ~2 hours (≤1 hour hands-on), with optional post-conjugation services at CellMosaic® for analytical characterization and DOL determination.
Labeling Chemistry
Protocol
Schematic workflow diagram for preparing AqT® biotin labeled ADC within 2 hours, starting with 3 mg of ADC. (Reagent volume will vary if the amount of ADC is less than 3 mg).
Other Details
The information in this document is subject to change without notice. CellMosaic® assumes no responsibility for any errors or omissions that may appear in this document. Under no circumstances shall CellMosaic be liable, whether in contract, tort, warranty, or under any statute or on other legal theory, for special, incidental, indirect, punitive, multiple, or consequential damages related to or arising from this document, including but not limited to the use of this product thereof.CellMosaic’s products, including but not limited to AqT®, NeIon™, oxLink™ and sxLink™ (collectively, the “Products”), are covered by, or are the subject of, one or more issued patents and pending patent applications, including without limitation: 9,688,663 B2; 8,907,079 B2; 9,511,150 B2; 9,907,854 B2; 9,346,833 B2; 9,518,067 B2; CN104066451B; CN107043339B; CA 2,841,313; EP 2734238 B1; AU2012284055; JP 6240599 B2; and corresponding foreign patents and patent applications. The purchase of the Product conveys solely a limited, non-exclusive, non-transferable, non-sublicensable license to use the Product only for the purchaser’s internal research and development purposes. No right or license is granted, either expressly or by implication, estoppel, or otherwise, under any patent, trademark, copyright, or other intellectual property right of CellMosaic, except as expressly stated herein. Any commercial use of the Product is strictly prohibited without a separate written agreement from CellMosaic. Prohibited commercial uses include, without limitation: (a) the sale, lease, licensing, distribution, or other transfer of the Product or any materials derived from or produced using the Product; (b) the sale, lease, licensing, or other grant of rights to use the Product or any materials derived from or produced using the Product; and (c) the use of the Product to perform services for a fee or other consideration for third parties, including without limitation contract research, screening services, or diagnostic or therapeutic applications. For information regarding commercial licensing or collaboration, please contact us at info@cellmosaic.com.
